invasive candidiasis – Page 7

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Virulence factors of Candida spp. isolated from COVID-19 patients: hydrolytic enzyme activity and biofilm formation

mycolabadmin

During the COVID-19 pandemic, many hospitalized patients developed fungal infections caused by Candida yeasts alongside their coronavirus infection. Researchers studied 71 Candida samples from COVID-19 patients to understand how these fungi cause disease by examining three damaging enzymes they produce and their ability to form protective biofilm layers. The findings showed that these fungi are highly virulent, producing strong enzyme activity that helps them invade tissues and resist treatment, which helps explain why these infections are particularly dangerous in COVID-19 patients.

Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery

mycolabadmin

Fungal infections like cryptococcal meningitis and invasive aspergillosis are becoming increasingly difficult to treat because fungi form protective structures called biofilms that resist our current medications. Researchers are using advanced techniques like mass spectrometry to identify the proteins that help fungi build these biofilms, combined with artificial intelligence tools to design new drugs that could break down these protective shields. This combined approach offers hope for developing better antifungal treatments that could save millions of lives.

Exploring the Antifungal Potential of Lawsone-Loaded Mesoporous Silica Nanoparticles Against Candida albicans and Candida glabrata: Growth Inhibition and Biofilm Disruption

mycolabadmin

Researchers developed a new antifungal treatment by loading lawsone (a compound from henna plants) into tiny particles called mesoporous silica nanoparticles. When tested against common fungal infections caused by Candida bacteria, this nano-formulation was more effective than lawsone alone at killing the fungi and breaking down protective biofilm structures. The treatment showed no harm to normal human cells, suggesting it could be a promising natural alternative to treat stubborn fungal infections that resist current antifungal drugs.

Candida albicans Goliath cells pioneer biofilm formation

mycolabadmin

When Candida albicans fungi run out of zinc, they transform into larger cells called ‘Goliath cells’ that are exceptionally sticky to plastic surfaces. Scientists found that these Goliath cells are much better at sticking to catheters and other medical devices than regular yeast cells, even when blood is flowing past them. This discovery helps explain why fungal infections on catheters are so common and could lead to better ways to prevent these dangerous infections that affect hospitalized patients.

Candidemia due to Candida lambica in a neutropenic oncology patient: A rare case report

mycolabadmin

A 56-year-old cancer patient developed a rare blood infection caused by an unusual yeast called Candida lambica while receiving chemotherapy. Despite taking antifungal medication for prevention, the patient developed a serious fever and low white blood cell count. Doctors identified the infection through genetic testing and treated it with a different antifungal drug called voriconazole, which successfully cleared the infection.

Vesicle inhibition reduces Candida biofilm resistance

mycolabadmin

Researchers found that common FDA-approved drugs designed to block vesicle production in human cells can also reduce the protective matrix that Candida fungus builds around itself in biofilms. By combining these vesicle-blocking drugs with the antifungal fluconazole, the scientists were able to kill biofilm-forming Candida more effectively than either treatment alone. This discovery suggests a new approach to treating stubborn fungal infections on medical devices like catheters, potentially eliminating the need to surgically remove infected equipment.

Antimicrobial and antiparasitic potential of lupeol: antifungal effect on the Candida parapsilosis species complex and nematicidal activity against Caenorhabditis elegans

mycolabadmin

Researchers tested a natural compound called lupeol against disease-causing yeasts and parasitic worms. Lupeol successfully killed or inhibited the growth of Candida yeast species that are becoming resistant to current medications. The compound also showed strong activity against parasitic roundworms. This discovery suggests lupeol could be developed as a new treatment option for fungal and parasitic infections.

Recognizing the Importance of Public Health Mycology

mycolabadmin

This editorial highlights how fungal infections are a growing but overlooked global health crisis, killing about 2.5 million people annually. The paper brings together seven research articles studying different fungal diseases, from lung infections to skin conditions, showing how these diseases spread differently in different populations and how resistance to antifungal medications is increasing. The authors emphasize that better testing, treatment access, and worldwide disease tracking are urgently needed, especially in poorer countries where the burden of fungal disease is highest.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections in people with weakened immune systems. This study reviewed and analyzed three clinical trials to compare how well isavuconazole works compared to other antifungal drugs. The results showed that isavuconazole is just as effective as other antifungals but has fewer side effects, particularly fewer problems with liver health and drug-related adverse events. This makes isavuconazole a good alternative choice for patients who cannot use other antifungal medications or who are at risk of liver damage.

Disease: invasive candidiasis